Abstract-Women with hypertensive disorders of pregnancy have an increased risk of subsequent heart failure and cardiovascular disease when compared with women with normotensive pregnancies. Although the mechanisms underlying these findings are unclear, elevated levels of the biomarker activin A are associated with myocardial dysfunction and may have predictive value. We hypothesized that elevated levels of antepartum activin A levels would correlate with postpartum cardiac dysfunction in women with hypertensive disorders of pregnancy. We prospectively studied 85 women to determine whether increased antepartum activin A levels were associated with cardiac dysfunction at 1 year postpartum as measured by global longitudinal strain. Thirty-two patients were diagnosed with preeclampsia, 28 were diagnosed with gestational or chronic hypertension, and the remainder were nonhypertensive controls. Activin A levels were measured with ELISA both in the third antepartum trimester and at 1 year postpartum. Comprehensive echocardiograms including measurement of global longitudinal strain were also performed at enrollment and at 1 year postpartum. Antepartum activin A levels correlated with worsening antepartum global longitudinal strain (r=0.70; P=0.0001). Across the entire cohort, elevated antepartum activin A levels were associated with the development of abnormal global longitudinal strain at 1 year (C statistic 0. 
H ypertensive disorders of pregnancy (HDP) affect 5% to 10% of all pregnant women and, along with hyperglycemia and gestational diabetes mellitus, are among the most common medical complications of pregnancy. [1] [2] [3] HDP are pregnancy specific and composed of 4 diseases: chronic hypertension, gestational hypertension, preeclampsia, and superimposed preeclampsia. Although HDP was once considered a disease of pregnancy, current data suggest that postpregnancy patients with HDP have an increased long-term risk of heart failure, ischemic heart disease, stroke, and death when compared with women with normotensive pregnancies. 4 In patients with preeclampsia, the likelihood of developing congestive heart failure and coronary heart disease is elevated as early as 1 year after delivery. 5 Accumulating data suggest that activin A, a member of the TGF-β (transforming growth factor-β) superfamily and implicated in the pathogenesis of preeclampsia, may play a central role in the development of heart failure. 6, 7 In a mouse model of dilated cardiomyopathy, infusion of an activin A antibody transiently improved cardiac function. 8 A 2017 study also found that serum activin A levels are elevated in women with HDP compared with normotensive controls and correlate with mean arterial pressure and proteinuria. 9 Although incompletely understood, potential mechanisms linking activin A to heart failure include aberrant cardiomyocyte remodeling, endothelial dysfunction, and myocardial fibrosis.
In HDP, cardiac function may be impaired even before the onset of clinical symptoms. Concentric hypertrophy, often accompanied by myocardial fibrosis, 10 induces changes in left ventricular geometry. Although these changes are not detectable by conventional echocardiography, they can be assessed using echocardiographic measurements of global longitudinal strain (GLS). 11 The ability of GLS measurement to predict heart failure has been documented in both animal models and human studies. [12] [13] [14] [15] GLS has also been used to diagnose antepartum left ventricular systolic dysfunction in women with HDP. 16, 17 Although most data on the long-term cardiovascular risk associated with HDP have focused on stage C (symptomatic) heart failure, few data have characterized the onset and progression of asymptomatic CVD in HDP women. Moreover, no known mechanistic or predictive biomarkers predict the risk of subsequent CVD development among women with HDP.
We hypothesized that in women with HDP, increased antepartum activin A levels would be associated with postpartum cardiac dysfunction. Our prespecified primary analysis was the association between antepartum activin A levels and postpartum cardiac dysfunction using GLS. We also performed an exploratory analysis to evaluate the relationship between postpartum activin levels and measurements of diastolic function and mean arterial pressures.
Methods
The authors declare that all supporting data are available within the article.
Study Design and Oversight
We conducted a prospective case-control study at the University of Chicago Medical Center and Beth Israel Deaconess Medical Center (Boston, MA) in accordance with institutional policies and institutional review board approval. Written informed consent was obtained from all patients. All data and supporting materials have been provided with the published article.
Human Subjects
We enrolled 85 pregnant women who delivered at the University of Chicago or Beth Israel Deaconess Medical Center between July 2013 and November 2016. Inclusion criteria included women at least 18 years of age with a singleton gestation of <41 weeks. Exclusion criteria included preexisting cardiomyopathy, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, or labor. Enrollment occurred when patients were admitted to labor and delivery or the antepartum floor, or during routine prenatal visits. Patients were classified into 3 groups using ACOG criteria (American College of Obstetricians and Gynecologists) 18 : no HDP, chronic or gestational hypertension, and preeclampsia. Preeclampsia was defined as blood pressure ≥140 mm Hg systolic or ≥90 mm Hg diastolic on 2 occasions at least 4 hours apart, and a urine protein (mg)/creatinine (mg) ratio ≥0.3 or ≥300 mg in 24 hours occurring after 20 weeks of gestation. In the absence of proteinuria, preeclampsia criteria were met if the patient had evidence of any endorgan damage. Severe preeclampsia were defined as severe hypertension (defined as systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥105 mm Hg, measured twice) or hypertension with any of the following features: thrombocytopenia (<100 000 platelets/mL), renal insufficiency (serum creatinine concentrations >1.1 mg/dL or a doubling of the serum creatinine concentration), impaired liver function (elevated serum liver transaminases, alanine transaminase or aspartate transaminase ≥80 U/L), pulmonary edema, or cerebral or visual symptoms. The last author (S.R.), a maternal-fetal medicine specialist, confirmed all clinical diagnoses. All clinical data were extracted from patient records.
Echocardiography
Transthoracic echocardiograms were performed at the time of enrollment and again 12 months after delivery by an experienced sonographer blinded to both the subjects' diagnosis and the levels of activin A. Echocardiographic measurements were performed as previously described 16 and included Doppler and diastolic measurements (E/A ratio, mitral valve inflow deceleration time, and E′). Simpson's biplane disc method was used to calculate ejection fraction and left atrial volume and left ventricular mass index (LVMI) was calculated using the area-length method. 19 Fully automated TomTec software (AutoStrain; TomTec Image-Arena 1.2, Unterschleissheim, Germany) was used for GLS measurement. 20 The researcher analyzing the echocardiographic data was blinded to patients' disease status.
Measurement of Circulating Activin Levels
Venous blood samples were collected within 24 hours of the enrollment echocardiogram and again 12 months after delivery. Blood samples were centrifuged for 8 minutes at −4°C, and the plasma was then aliquoted, labeled with a study ID, and stored at −70°C. A single operator blinded to clinical information performed activin A assays on each plasma sample in duplicate using commercially available kits (Ansh Laboratories, Webster, TX).
Statistical Analysis
Data were assessed with the use of parametric or nonparametric t tests as appropriate and presented as mean (±SDs) or median (quartile 1-quartile 3) depending on the data distribution. Normality was assessed with the Shapiro-Wilk test. Categorical variables are reported as frequencies and proportions and assessed with a χ 2 or Fisher exact test. An abnormal GLS was defined as ≤−18% based on previously published studies. 16, 21, 22 Antepartum activin A levels were classified as abnormal if greater than the 99th percentile of normal group values per American Heart Association guidelines on biomarker analyses. 23 To assess the relationship between antepartum activin A and postpartum GLS at 12 months, univariate and multivariable logistic regression models were constructed. We dichotomized GLS and activin A levels as described above. Multivariable models were created and adjusted using prespecified clinically relevant confounders including age, racial category, body mass index, and postpartum mean arterial pressure. Because we determined that gestational age at the sample was significantly different between groups during post hoc analysis, we performed an additional analysis that included gestational age at the time of the sample. Logistic regression was used to describe the association between antepartum activin A levels and postpartum GLS and is reported as receiver-operating characteristic analyses. Additional secondary analyses examined the correlation between postpartum activin A levels and mean arterial pressures, LVMI, and echocardiographic indices of diastolic function. Statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC). Two-tailed P values of <0.05 were considered statistically significant.
Results

Demographics
A total of 85 parturients were included in the analysis. Baseline characteristics are shown in Table 1 . Thirty-two (38%) patients were diagnosed with preeclampsia, 28 (33%) were diagnosed with gestational or chronic hypertension, and 25 (29%) did not have an HDP. Preeclamptic women had higher body mass index values (P=0.01) and were more likely to have elevated postpartum blood pressures and stage 1 and stage 2 hypertension than women without HDP (P=0.04). Women with chronic or gestational hypertension also had higher body mass index values and mean arterial pressures than parturients without HDP (both P<0.003). Among women with no HDP, 19% had premature rupture of membranes, 20% had preterm labor, and 10% had placenta previa.
Activin A Measurements
The median gestational age at sample collection for preeclamptic women was 32 
Echocardiographic Measurements
Cardiac systolic and diastolic function indices for all 3 patient groups are compared in Table 2 . Antepartum subclinical cardiac dysfunction (defined as GLS ≤−18%) was more common in preeclamptic women than in normal women or those with chronic hypertension (31%, 0%, and 6% respectively; P<0.001). At 1 year postpartum, abnormal GLS was more common in women who had had preeclampsia (60%) than in women who had had chronic or gestational hypertension (44%) or women without HDP (20%; P=0.02). Postpartum LVMI, septal wall thickness, and deceleration times were all higher in women who had had preeclampsia or gestational or chronic hypertension than in women without a HDP (Table 2) .
Correlation Between Activin and Echocardiography Measurements
Across the entire study cohort, abnormal antepartum activin A levels were associated with the presence of abnormal postpartum GLS at 1 year (C statistic 0.74; P=0.004; Table 3 ). This association persisted (C=0.90) after multivariable adjustment for maternal age, racial category, preterm delivery, mean arterial blood pressure, and body mass index. Post hoc adjustment for gestational age at the time of sample collection (instead of gestational age at delivery) did not alter our results (C statistic 0.94; P=0.01; Figure) . Antepartum activin A levels also correlated with worsening antepartum GLS (r=0.70; P=0.0001). Postpartum activin A levels were considerably lower than antepartum levels but also correlated with increasing LVMI (P=0.02) and decreasing E′ values (P=0.01).
Discussion
In this prospective study of cardiac dysfunction in patients with HDP and nonhypertensive controls, we observed that subclinical cardiac dysfunction, as manifested by abnormal GLS, is present in women with antepartum HDP and persists 12 months after delivery. In addition, we observed that abnormal levels of antepartum activin A correlated with abnormal GLS during pregnancy and was associated with an abnormal GLS at 1 year postpartum. These findings remained robust after adjustment for relevant confounders including mean arterial pressure and gestational age at the time of sample collection. We also found that postpartum levels of activin A correlated with increasing LVMI and worsening diastolic function. Our data are consistent with earlier work on cardiac function in preeclampsia. 10, [24] [25] [26] We expand on this work by demonstrating an association between antepartum levels of activin A, a cardiac biomarker, and cardiac dysfunction at 1 year postpartum. Prior studies suggest that activin A levels correlate with increased cardiac fibrosis, which has been implicated in the development of maladaptive remodeling, 27 hypertension, heart failure, myocardial infarction, and arrhythmias. In nonpregnant patients with heart failure, activin A levels are elevated in comparison to healthy volunteers, and higher activin A levels correlate with worsening heart failure. 28 In a 2016 mouse study, an infusion of an activin A antibody transiently improved cardiac function for a 2-week period. 8 The antepartum activin A values that we report differ slightly from prior cohort studies. Reddy et al 29 examined circulating levels of activin A at parturition and found median activin A levels of 19.8 (IQR: 8-79) ng/mL in preeclamptic women and 8.8 (IQR: 5-28) ng/mL in pregnant controls. In contrast, our antepartum activin values ranged from 3.3 in normal patients to 26 in preeclamptic women. Although the reason for these slight discrepancies in antepartum activin measurements are unclear, we think that the slightly higher preeclamptic activin A levels and lower normal levels we found may be because of systemic inflammation or assay variation. Lower postpartum activin measurements may be because the placenta, a major source of maternal circulating activin A, is removed during delivery. 30 In pregnant women with HDP, already present cardiac dysfunction may increase placental stress (hypoxic or otherwise), which triggers activin A release. 31, 32 High activin levels in such patients may, thus, serve as a marker for cardiovascular disease.
The association between HDP and postpartum cardiovascular disease is well established. 10, 26, [33] [34] [35] [36] Chronic postpartum cardiovascular diseases associated with HDP include hypertension, heart failure, metabolic syndrome, CVD, and stroke or ischemic heart disease. Asymptomatic left ventricular dysfunction may develop as early as 1 year post-delivery, and chronic hypertension may be present within 2 years. 33, 36 Our work adds to those findings by correlating circulating levels of antepartum activin with postpartum cardiac dysfunction and postpartum activin levels with myocardial remodeling, and diastolic function. Our data also raise the possibility of that women at risk for delayed cardiovascular complications of HDP may be identified before delivery via measurement of blood activin levels.
We found that along with cardiac dysfunction, stage 1 and stage 2 hypertension were both more common at 1 year postpartum in women who had had a preeclamptic delivery than in healthy parturients. Detecting such chronic cardiovascular disease during pregnancy, thus, provides an opportunity for mitigating or even reversing the progression to clinically symptomatic cardiovascular disease. Previous work suggests that biomarker-based screening in patients at risk for heart failure, followed by referral to a cardiovascular specialist, can decrease the incidence of asymptomatic cardiac dysfunction or new-onset heart failure. 37 A 2017 study of elderly patients with subclinical heart failure found that adherence to cardioprotective therapy for subclinical heart failure was associated with a 77% lower rate of death or frank heart failure. 21 Although the efficacy of early treatment in women of childbearing age is unclear, our data introduce the possibility of monitoring such women via a blood test rather than serial echocardiograms.
Our observational study has limitations. Because we only monitored patients for 12 months postpartum, we cannot say whether the changes in strain and biomarker levels we observed at 1 year persist or resolve beyond the 1-year mark. Second, because echocardiograms and blood draws were performed on study enrollment, which was typically in the third trimester, we do not know whether our patients had abnormal echocardiograms or abnormal activin A levels before study entry (in the first trimester or even before pregnancy). In addition, given the observational nature of the study and the fact that both activin A levels and echocardiographic measurements were performed at the same time point, no causal inference can be drawn about the relationship between activin and development of cardiac dysfunction in our cohort of women with HDP. Finally, we did not measure other cardiac biomarkers in the TGF-β family. Additional research should evaluate the relationship between postpartum cardiac dysfunction and other cardiac biomarkers in the TGF-β family.
Perspectives
The biomarker activin A correlates with cardiac dysfunction both before delivery and at 1 year postpartum in women with HDP. Antepartum activin A measurement may be a useful tool for identifying patients at risk for postpartum development of cardiovascular disease. Further work is needed to better understand how activin A can be used to identify and track the development of long-term postpartum cardiovascular disease in women with HDP.
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Figure.
Receiver-operating characteristic curves for patients stratified by models with clinical characteristics only (C=0.76), abnormal antepartum activin A only (C=0.74), and the addition of both clinical and biomarker characteristics (C=0.93). Clinical characteristics included maternal race, mean arterial blood pressure, and gestational age at the time of the blood sample.
